<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7751403</article-id><article-id pub-id-type="doi">10.1080/14756366.2020.1862100</article-id><article-id pub-id-type="publisher-id">1862100</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Development of 2-oindolin-3-ylidene-indole-3-carbohydrazide derivatives as novel apoptotic and anti-proliferative agents towards colorectal cancer cells</article-title><alt-title alt-title-type="left-running-head">W. M. Eldehna et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eldehna</surname><given-names>Wagdy M.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>Abo-Ashour</surname><given-names>Mahmoud F.</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Al-Warhi</surname><given-names>Tarfah</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><name><surname>Al-Rashood</surname><given-names>Sara T.</given-names></name><xref ref-type="aff" rid="AF0004">d</xref><xref ref-type="corresp" rid="AN0002"/></contrib><contrib contrib-type="author"><name><surname>Alharbi</surname><given-names>Amal</given-names></name><xref ref-type="aff" rid="AF0004">d</xref></contrib><contrib contrib-type="author"><name><surname>Ayyad</surname><given-names>Rezk R.</given-names></name><xref ref-type="aff" rid="AF0005">e</xref></contrib><contrib contrib-type="author"><name><surname>Al-Khayal</surname><given-names>Khayal</given-names></name><xref ref-type="aff" rid="AF0006">f</xref></contrib><contrib contrib-type="author"><name><surname>Abdulla</surname><given-names>Maha</given-names></name><xref ref-type="aff" rid="AF0006">f</xref></contrib><contrib contrib-type="author"><name><surname>Abdel-Aziz</surname><given-names>Hatem A.</given-names></name><xref ref-type="aff" rid="AF0007">g</xref></contrib><contrib contrib-type="author"><name><surname>Ahmad</surname><given-names>Rehan</given-names></name><xref ref-type="aff" rid="AF0006">f</xref></contrib><contrib contrib-type="author"><name><surname>El-Haggar</surname><given-names>Radwan</given-names></name><xref ref-type="aff" rid="AF0008">h</xref></contrib><aff id="AF0001"><label>a</label><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University</institution>, <city>Kafrelsheikh</city>, <country>Egypt</country></aff><aff id="AF0002"><label>b</label><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University</institution>, <city>Badr City</city>, <country>Egypt</country></aff><aff id="AF0003"><label>c</label><institution>Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University</institution>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff><aff id="AF0004"><label>d</label><institution>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University</institution>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff><aff id="AF0005"><label>e</label><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University</institution>, <city>Cairo</city>, <country>Egypt</country></aff><aff id="AF0006"><label>f</label><institution>Colorectal Research Chair, Department of Surgery, King Khalid University Hospital, King Saud University College of Medicine</institution>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff><aff id="AF0007"><label>g</label><institution>Department of Applied Organic Chemistry, National Research Center</institution>, <city>Giza</city>, <country>Egypt</country></aff><aff id="AF0008"><label>h</label><institution>Pharmaceutical Chemistry Department, Faculty of Pharmacy, Helwan University</institution>, <city>Cairo</city>, <country>Egypt</country></aff></contrib-group><author-notes><fn id="AUFN1"><p content-type="appended text">Supplemental data for this article can be accessed <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1862100"><underline>here</underline></ext-link>.</p></fn><corresp id="AN0001">CONTACT Wagdy M. Eldehna <email>wagdy2000@gmail.com</email><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University</institution>, <city>Kafrelsheikh</city>, <country>Egypt</country></corresp><corresp id="AN0002">Sara T. Al-Rashood <email>salrashood@ksu.edu.sa</email><institution>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University</institution>, <city>Riyadh</city>, <country>Saudi Arabia</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>12</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>36</volume><issue>1</issue><fpage seq="30">319</fpage><lpage>328</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_36_1862100.pdf"/><abstract><title>Abstract</title><p>Mitochondrial anti-apoptotic Bcl2 and BclxL proteins, are overexpressed in multiple tumour types, and has been involved in the progression and survival of malignant cells. Therefore, inhibition of such proteins has become a validated and attractive target for anticancer drug discovery. In this manner, the present studies developed a series of novel isatin&#x02013;indole conjugates (<bold>7a-j</bold> and <bold>9a-e</bold>) as potential anticancer Bcl2 and BclxL inhibitors. The progression of the two examined colorectal cancer cell lines was significantly inhibited by all of the prepared compounds with IC<sub>50</sub> ranges132&#x02013;611&#x02009;nM compared to IC<sub>50</sub>&#x02009;=&#x02009;4.6&#x02009;&#x000b5;M for <bold>5FU</bold>, against HT-29 and IC<sub>50</sub> ranges 37&#x02013;468&#x02009;nM compared to IC<sub>50</sub>&#x02009;=&#x02009;1.5&#x02009;&#x000b5;M for <bold>5FU</bold>, against SW-620. Thereafter, compounds <bold>7c</bold> and <bold>7g</bold> were selected for further investigations. Interestingly, both compounds exhibited selective cytotoxicity against both cell lines with high safety to normal fibroblast (HFF-1). In addition, both compounds <bold>7c</bold> and <bold>7g</bold> induced apoptosis and inhibited Bcl2 and BclxL expression in a dose-dependent manner. Collectively, the high potency and selective cytotoxicity suggested that conjugates <bold>7c</bold> and <bold>7g</bold> could be a starting point for further optimisation to develop novel pro-apoptotic and antitumor agents towards colon cancer.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Anti-proliferative indoles</kwd><kwd>apoptosis</kwd><kwd>isatin-indole</kwd><kwd>Bcl2/BclxL inhibitors</kwd><kwd>colorectal cancer</kwd><kwd>western blotting</kwd></kwd-group><counts><fig-count count="5"/><table-count count="1"/><page-count count="10"/><word-count count="6320"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Cancer is a group of diseases that is characterised by uncontrolled and rapid cell proliferation and differentiation mechanisms with the potential to invade or spread to other body parts<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. Since several decades, cancer has been one of the main world health problems and is still considered a serious leading cause of death worldwide. Early strategies of cancer treatment were based on the unspecific induction of cell death mainly targeting the replication machinery<xref rid="CIT0002" ref-type="bibr"><sup>2&#x02013;5</sup></xref> and/or the DNA synthesis<xref rid="CIT0006" ref-type="bibr"><sup>6&#x02013;9</sup></xref>. Therefore, the traditional anticancer drugs were associated with severe adverse effects due to the unselective toxicity towards the normal cells in addition to the resistance emerged towards them<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>. Thus, the development of effective and safe new antitumour drugs with increased selectivity towards cancer cells is still an active search<xref rid="CIT0010" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref>. On the other hand, recent strategies of targeted therapies target specific biomarkers essential for the regulation of cancer cells proliferation and/or cell apoptosis such as deregulated, mutated, or overexpressed proteins<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref> and thus, selectively affect cancer cells or their supporting environment with minimum effects on normal cells<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>. Among these targets are the pro-apoptotic and anti-apoptotic proteins that control the cellular apoptosis<xref rid="CIT0014" ref-type="bibr"><sup>14&#x02013;16</sup></xref>.</p><p>Apoptosis, a form of programmed cell death takes place in multicellular organisms, is a series of biochemical events that result in characteristic cell changes and death<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>. Apoptosis could be launched through one of two pathways (intrinsic pathway and extrinsic pathway). The mitochondria-dependent apoptotic pathway (intrinsic pathway), one of the main pathways of induction of the cell apoptosis<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref>, is controlled by the Bcl2 proteins family. The Bcl2 family members have dual functions; some are anti-apoptotic Bcl2 proteins, such as Bcl2 and BclxL that inhibit apoptosis, while others are pro-apoptotic Bcl2 proteins such as Bax and Bak that promote apoptosis<xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>. In this regard, it was reported that most of cancer cells are characterised by over-expression of the anti-apoptotic Bcl2 proteins which could lead to apoptosis prevention as well as drug resistance<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>. Thus, the development of anti-apoptotic Bcl2 proteins inhibitors has become an important strategy for introducing potential anti-cancer agents<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>. In this manner, several heterocyclic scaffolds including isatin<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref> were developed as candidates targeting Bcl2 proteins.</p><p>Isatin (1<italic>H</italic>-indole-2,3-dione), as a special class in drug design and discovery, represents one of the most favourable scaffolds of heterocyclic systems which possesses many interesting biological activities including anti-SARS-CoV-2<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>, antimicrobial<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref>, anticonvulsant<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref> and mainly anticancer<xref rid="CIT0026" ref-type="bibr"><sup>26&#x02013;28</sup></xref>. Therefore, isatin nucleus was broadly used by our group for the development of diverse effective oxindole-based small molecules (structures <bold>I</bold>&#x02013;<bold>III</bold><xref rid="CIT0029" ref-type="bibr"><sup>29&#x02013;31</sup></xref>, <xref ref-type="fig" rid="F0001">Figure 1</xref>) with anticancer activities that target different enzymatic and cellular targets such as inhibition of cancer-related carbonic anhydrase IX isoform<xref rid="CIT0032" ref-type="bibr"><sup>32&#x02013;33</sup></xref>, inhibition of different kinases<xref rid="CIT0034" ref-type="bibr"><sup>34&#x02013;35</sup></xref>, in addition to apoptosis induction in different human cancer cell lines<xref rid="CIT0036" ref-type="bibr"><sup>36&#x02013;37</sup></xref>.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Chemical structures for some reported isatin-based anticancer conjugates (<bold>I-III</bold>), and the target conjugates (<bold>7a-j</bold> and <bold>9a</bold>-<bold>e</bold>).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1862100_F0001_C"/></fig><p>Motivated by the aforementioned findings and in continuation to our previous work, in the present study, a novel series of isatin/indole conjugates (<bold>7a-j</bold> and <bold>9a-e</bold>, <xref ref-type="fig" rid="F0001">Figure 1</xref>) were designed and synthesised. The antiproliferative effect of the new compounds against HT-29 and SW-620 colorectal cancer cell lines were examined. In addition, the levels of the mitochondria-related anti-apoptotic proteins Bcl2 and BclxL in HT-29 and SW-620 colorectal cancer cell lines after incubation with isatin derivatives <bold>7c</bold> and <bold>7g</bold> were determined.</p></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Results and discussion</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Chemistry</title><p>The synthetic strategies deliberate for the development of the final compounds (<bold>7a-j</bold> and <bold>9a-e</bold>) were illustrated in <xref ref-type="scheme" rid="s0001 s0002">Schemes 1&#x02013;2</xref>. In <xref ref-type="scheme" rid="s0001">Scheme 1</xref>, indole <bold>1</bold> was subjugated to formylation <italic>via</italic> Vilsmeier haack reaction to produce 1<italic>H</italic>-indole-3-carbaldehyde <bold>2</bold>, in which the CHO functionality was oxidised by KMnO<sub>4</sub> in acetone to furnish 1<italic>H</italic>-indole-3-carboxylic acid <bold>3</bold>. Then, the acid analogue <bold>3</bold> was subjected to esterification through refluxing in dry methanol to get the carboxylate analogue <bold>4</bold>, where the ester group reacted with hydrazine hydrate in methyl alcohol to produce the key intermediate 1<italic>H</italic>-indole-3-carbohydrazide <bold>5</bold>. Finally, the key intermediate <bold>5</bold> was condensed with different isatin derivatives <bold>6a-j</bold> in glacial acetic acid to give the final targeted compounds <bold>7a-j</bold>.</p><fig id="s0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthesis of target 2-oxindolin-3-ylidene-indole-3-carbohydrazide <bold>7a-j</bold>; (<bold>i</bold>) DMF/POCl<sub>3</sub>/reflux 8&#x02009;h, (<bold>ii</bold>) KMnO<sub>4</sub>/Acetone/Stirring at R.T 12&#x02009;h, (<bold>iii</bold>) Dry methanol/H<sub>2</sub>SO<sub>4</sub> (Cat.)/reflux 7&#x02009;h, (<bold>iv</bold>) hydrazine hydrate/methanol/reflux 4&#x02009;h, (<bold>v</bold>) Glacial acetic acid/reflux (5&#x02013;7) h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1862100_SCH0001_B"/></fig><p>On the other hand, in <xref ref-type="scheme" rid="s0002">Scheme 2</xref>, three isatins <bold>6a</bold>, <bold>6c</bold> and <bold>6d</bold> were alkylated with methyl iodide, propyl bromide and benzyl bromide in DMF with the presence of K<sub>2</sub>CO<sub>3</sub> and catalytic amount of KI to give the <italic>N</italic>-substituted isatin derivatives <bold>8a-e</bold>, which heated under reflux with the carbohydrazide <bold>5</bold> in acetic acid to furnish the final compounds <bold>9a-e</bold>, respectively. The structure of the synthesised 2-oxindolin-3-ylidene-indole-3-carbohydrazide was confirmed under the basis of spectral and elemental analyses which were in full agreement with the proposed structures.</p><fig id="s0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Synthesis of target <italic>N</italic>-substituted 2-oxindolin-3-ylidene-indole-3-carbohydrazide <bold>9a-e</bold>; (<bold>i</bold>) R-Br/DMF/K<sub>2</sub>CO<sub>3</sub>/KI (Cat.)/reflux 5&#x02009;h, (<bold>ii</bold>) Glacial acetic acid/reflux (5&#x02013;7) h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1862100_SCH0002_B"/></fig></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Biological evaluation</title><sec id="S0002-S2002-S3001" disp-level="3"><label>2.2.1.</label><title>Anti-proliferative activity against HT-29 and SW-620 colorectal cancer cell lines</title><p>The anti-proliferative potential of the final compounds (<bold>7a-j</bold> and <bold>9a-e</bold>) was examined against two human colorectal cancer HT-29 and SW-620 cell lines. While, HT-29 is an adenocarcinoma cell line, SW-620 represents metastatic cancer cell line. These effects were compared with known anti-cancer drug, 5-Fluorouracil (<bold>5FU</bold>) commonly used in colorectal cancer treatment. All of the compounds were found to inhibit the cell viability of cancer cells with varied sub-micro-molar efficacy. The IC<sub>50</sub> values ranged from 105 to 611&#x02009;nM for all compounds were calculated using Graph Pad prism 8 (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p><italic>In vitro</italic> anti-proliferative actions of compounds <bold>7a-j</bold> and <bold>9a-e</bold> towards HT-29 and SW-620 colorectal cancer cell lines.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th colspan="6" align="left"><inline-graphic xlink:href="IENZ_A_1862100_ILG0001.gif"/><hr/></th></tr><tr><th rowspan="2" align="left">Comp.</th><th rowspan="2" align="center">R</th><th rowspan="2" align="center">R<sub>1</sub></th><th rowspan="2" align="center">R<sub>2</sub></th><th colspan="2" align="center"><bold>IC<sub>50</sub> (nM)</bold><sup>a</sup><hr/></th></tr><tr><th align="center">HT-29</th><th align="center">SW-620</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>7a</bold></td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char=".">408</td><td align="char" char=".">145</td></tr><tr><td align="left"><bold>7b</bold></td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="char" char=".">611</td><td align="char" char=".">175</td></tr><tr><td align="left"><bold>7c</bold></td><td align="center">Cl</td><td align="center">H</td><td align="center">H</td><td align="char" char=".">206</td><td align="char" char=".">188</td></tr><tr><td align="left"><bold>7d</bold></td><td align="center">Br</td><td align="center">H</td><td align="center">H</td><td align="char" char=".">320</td><td align="char" char=".">133</td></tr><tr><td align="left"><bold>7e</bold></td><td align="center">CH<sub>3</sub></td><td align="center">H</td><td align="center">H</td><td align="char" char=".">335</td><td align="char" char=".">253</td></tr><tr><td align="left"><bold>7f</bold></td><td align="center">OCH<sub>3</sub></td><td align="center">H</td><td align="center">H</td><td align="char" char=".">142</td><td align="char" char=".">37</td></tr><tr><td align="left"><bold>7g</bold></td><td align="center">OCF<sub>3</sub></td><td align="center">H</td><td align="center">H</td><td align="char" char=".">299</td><td align="char" char=".">279</td></tr><tr><td align="left"><bold>7h</bold></td><td align="center">NO<sub>2</sub></td><td align="center">H</td><td align="center">H</td><td align="char" char=".">132</td><td align="char" char=".">190</td></tr><tr><td align="left"><bold>7i</bold></td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="char" char=".">140</td><td align="char" char=".">468</td></tr><tr><td align="left"><bold>7j</bold></td><td align="center">CH<sub>3</sub></td><td align="center">CH<sub>3</sub></td><td align="center">H</td><td align="char" char=".">200</td><td align="char" char=".">187</td></tr><tr><td align="left"><bold>9a</bold></td><td align="center">H</td><td align="center">H</td><td align="center">CH<sub>3</sub></td><td align="char" char=".">176</td><td align="char" char=".">260</td></tr><tr><td align="left"><bold>9b</bold></td><td align="center">H</td><td align="center">H</td><td align="center">propyl</td><td align="char" char=".">525</td><td align="char" char=".">105</td></tr><tr><td align="left"><bold>9c</bold></td><td align="center">H</td><td align="center">H</td><td align="center">benzyl</td><td align="char" char=".">405</td><td align="char" char=".">283</td></tr><tr><td align="left"><bold>9d</bold></td><td align="center">Cl</td><td align="center">H</td><td align="center">propyl</td><td align="char" char=".">166</td><td align="char" char=".">290</td></tr><tr><td align="left"><bold>9e</bold></td><td align="center">Br</td><td align="center">H</td><td align="center">propyl</td><td align="char" char=".">290</td><td align="char" char=".">414</td></tr><tr><td align="left"><bold>5-FU</bold></td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="char" char=".">4600</td><td align="char" char=".">1500</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><label><sup>a</sup></label><p>IC<sub>50</sub> values are the mean&#x02009;&#x000b1;&#x02009;SD of three separate experiments.</p></fn></table-wrap-foot></table-wrap><p>Regarding the activity towards HT-29 cell line, all compounds showed superior activity to the reference drug (<bold>5FU</bold>) with IC<sub>50</sub> ranged from 132-611&#x02009;nM compared to IC<sub>50</sub>=4.6&#x02009;&#x000b5;M for <bold>5FU</bold>. Compound <bold>7h</bold> was the most active against HT-29 cell line with IC<sub>50</sub>=132&#x02009;nM that is approximately 35-fold more than <bold>5FU</bold>. Also, the results revealed that the <italic>N</italic>-alkylation of isatin moiety (series <bold>9a-e</bold>) resulted in diversified effect on the potency according to the alkyl group added and/or the substitution on indole moiety. For the unsubstituted indole (<bold>7a</bold>, IC<sub>50</sub>=408&#x02009;nM), while <italic>N</italic>-alkylation with CH<sub>3</sub>- group significantly increase the potency (<bold>9a</bold>, IC<sub>50</sub>=176&#x02009;nM) and <italic>N</italic>-alkylation with benzyl- group slightly increase the potency (<bold>9c</bold>, IC<sub>50</sub>=405&#x02009;nM), the <italic>N</italic>-alkylation with propyl group dramatically decrease the potency (<bold>9b</bold>, IC<sub>50</sub>=525&#x02009;nM). Furthermore, <italic>N</italic>-propylation of both chloro- (<bold>7c</bold>, IC<sub>50</sub>=206&#x02009;nM) and bromo- (<bold>7d</bold>, IC<sub>50</sub>=320&#x02009;nM) derivatives significantly increase the potency (<bold>9d</bold>, IC<sub>50</sub>=166&#x02009;nM) and (<bold>9e</bold>, IC<sub>50</sub>=290&#x02009;nM), respectively. Similarly, the activity towards SW-620 cell line of all compounds was more that <bold>5FU</bold> with IC<sub>50</sub> ranged from 37&#x02013;468&#x02009;nM compared to IC<sub>50</sub>=1.5&#x02009;&#x000b5;M for <bold>5FU</bold>. Compound <bold>7f</bold> was the most active against SW-620 cell line with IC<sub>50</sub>=37&#x02009;nM that is approximately 32 folds more than <bold>5FU</bold>. However, <italic>N</italic>-alkylation of isatin moiety resulted in reduction of potency for all series except for compounds <bold>9b</bold> (IC<sub>50</sub>=105&#x02009;nM) compared to compound <bold>7a</bold> (IC<sub>50</sub>=145&#x02009;nM) (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><p><xref ref-type="fig" rid="F0002">Figure 2</xref> illustrated that treatment of HT-29 and SW-620 cell lines with different concentrations of compounds <bold>7c</bold> and <bold>7g</bold> resulted in a dose-dependent inhibition of cell viability. Compound <bold>7c</bold> was found to inhibit HT-29 and SW-620 with IC<sub>50</sub>=188&#x02009;nM and 206&#x02009;nM, respectively (<xref ref-type="fig" rid="F0002">Figure 2(A,B)</xref>), whereas compound <bold>7g</bold> was found to exhibit IC<sub>50</sub> of 279&#x02009;nM against HT-29 and 299&#x02009;nM against SW-620 cell lines (<xref ref-type="fig" rid="F0002">Figure 2(C,D)</xref>), compared to the IC<sub>50</sub> for <bold>5FU</bold> that was found to be 1.5&#x02009;&#x000b5;M against HT-29 and 4.6&#x02009;&#x000b5;M against SW-620 cell lines.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Effect of Compound <bold>7c</bold> and <bold>7g</bold> on the cell viability. Different concentrations of compound <bold>7c</bold> and <bold>7g</bold> have been used to study its effect on cell viability by MTT assay. Results of percent viability vs concentration were plotted and the IC<sub>50</sub> was calculated for each cell line using Graph Pad prism 8. (A) HT-29 with compound <bold>7c</bold>, (B) SW-620 with compound <bold>7c</bold>, (C) HT-29 with compound <bold>7g</bold>, and (D) SW-620 with compound <bold>7g</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1862100_F0002_B"/></fig><p>Furthermore, to investigate the selective cytotoxicity of the tested compounds, the effect of compounds <bold>7c</bold> and <bold>7g</bold> was studied on normal human skin fibroblast (HFF-1). Compounds <bold>7c</bold> and <bold>7g</bold> were found to have no/or little effect on cell viability of HFF-1 (<xref ref-type="fig" rid="F0003">Figure 3(A,B)</xref>). This finding indicates that compounds <bold>7c</bold> and <bold>7g</bold> inhibited cell viability of cancer cells without affecting normal fibroblast.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Effect of Compounds <bold>7c</bold> and <bold>7g</bold> on HFF-1. HFF-1 fibroblast cells were treated with compound <bold>7c</bold> and <bold>7g</bold> for 24&#x02009;h and % viability was measured using MTT assay. (A) HFF-1 with compound <bold>7c</bold> and (B) HFF-1 with compound <bold>7g</bold>. </p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1862100_F0003_B"/></fig></sec><sec id="S0002-S2002-S3002" disp-level="3"><label>2.2.2.</label><title>Annexin V-FITC apoptosis assay</title><p>Induction of apoptosis is mainly considered as an important strategy for the development of new anti-proliferative agents<xref rid="CIT0038" ref-type="bibr"><sup>38</sup></xref>. Compounds <bold>7c</bold> and <bold>7g</bold> were further investigated for their potential role of apoptosis induction in the colorectal SW-620 cancer cell line (SW-620 cell line was selected because most of the new compounds showed significant potency more than HT-29 cell line). Exposure of SW-620 cells to compounds <bold>7c</bold> and <bold>7g</bold> resulted in the induction of apoptosis in a dose dependent manner (<xref ref-type="fig" rid="F0004">Figure 4</xref>). As shown in the results, compound <bold>7c</bold> at concentrations of 250&#x02009;nM and 500&#x02009;nM was able to induce approximately 5.2- and 10.66-fold, respectively, total apoptosis increase compared to the control for SW-620 cell line (<xref ref-type="fig" rid="F0004">Figure 4(A)</xref>). Similarly, compound <bold>7g</bold> induced approximately 7.3 and 9.6 fold total apoptosis increase compared to the control when incubated with SW-620 cell line at concentration of 250&#x02009;nM and 500&#x02009;nM, respectively (<xref ref-type="fig" rid="F0004">Figure 4(B)</xref>). These findings encouraged us to further investigate the effect of compounds <bold>7c</bold> and <bold>7g</bold> towards the anti-apoptotic mitochondrial markers Bcl2 and BclxL.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>(A) Annexin V apoptosis assay for compound <bold>7c</bold>. SW-620 cells were treated with compound <bold>7c</bold> (250 and 500&#x02009;nM) for 24&#x02009;h. Quadrant was set for the resulted dots population from the results of the negative auto-fluorescence and the statistical analysis was performed where the significance of data was assessed at <italic>p</italic> values<italic>&#x02009;&#x0003c;&#x02009;0.05</italic>. **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 control vs treated. (B) Annexin V apoptosis assay for compound <bold>7g</bold>. SW-620 cells were treated with compound <bold>7g</bold> (250 and 500&#x02009;nM) for 24&#x02009;h. Quadrant was set for the resulted dots population from the results of the negative auto-fluorescence and the statistical analysis was performed where the significance of data was assessed at <italic>p</italic> values<italic>&#x02009;&#x0003c;&#x02009;0.05</italic>. **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 control vs treated.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1862100_F0004_B"/></fig></sec><sec id="S0002-S2002-S3003" disp-level="3"><label>2.2.3.</label><title>Impact of compounds 7c and 7g on the anti-apoptotic (Bcl2, and BclxL) markers levels</title><p>Bcl2 and BclxL, as anti-apoptotic proteins, are known to be overexpressed in diverse tumours causing cancer cell survival and drug resistance<xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>. Inhibition of these proteins expression resulted in cancer cell death and has been exploited as a strategy for anticancer drug discovery<xref rid="CIT0015" ref-type="bibr"><sup>15&#x02013;16</sup></xref>. Treatment of SW-620 with compound <bold>7c</bold> resulted in a dose-dependent inhibition of Bcl2 and BclxL protein expression (<xref ref-type="fig" rid="F0005">Figure 5(A)</xref>). Compound <bold>7g</bold> was also found to inhibit Bcl2 and BclxL expression in SW-620 cells (<xref ref-type="fig" rid="F0005">Figure 5(B)</xref>). These findings thus indicate that compound <bold>7c</bold> and <bold>7g</bold> inhibited cell viability by inhibiting Bcl2 and BclxL resulting in the apoptosis.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>(A) Effect of compound <bold>7c</bold> on anti-apoptotic proteins. SW-620 cancer cells were treated with two concentrations of compound <bold>7c</bold> for 24&#x02009;h. Immunoblotting was performed with the indicated antibodies. The band densities were measured and the bar charts were created to compare the effect on proteins. The statistical analysis was performed where the significance of data was assessed at <italic>a p</italic> values<italic>&#x02009;&#x0003c;&#x02009;0.05</italic>. *** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; ** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 control vs treated. (B) Effect of compound <bold>7g</bold> on anti-apoptotic proteins. SW-620 cancer cells were treated with two concentrations of compound <bold>7g</bold> for 24&#x02009;h. Immunoblotting was performed with the indicated antibodies. The band densities were measured and the bar charts were created to compare the effect on proteins.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1862100_F0005_B"/></fig></sec></sec></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Conclusions</title><p>In the present work, a series of novel isatin-indole conjugates (<bold>7a-j</bold> and <bold>9a-e</bold>) was designed and synthesised as potential antiproliferative agents towards colon cancer cells with promising inhibitory activity against the anti-apoptotic Bcl2 and BclxL proteins. The cell growth of two examined colorectal cancer (HT-29 and SW-620) cell lines was significantly inhibited by all of the prepared compounds with IC<sub>50</sub> ranges 132&#x02013;611&#x02009;nM against HT-29 and IC<sub>50</sub> ranges 37&#x02013;468&#x02009;nM against SW-620 as compared to IC<sub>50</sub>=4.6 and 1.5&#x02009;&#x000b5;M for <bold>5FU</bold>, respectively. For further mechanistic and selective cytotoxicity studies, compounds <bold>7c</bold> and <bold>7g</bold> were examined and proved to exhibit selective cytotoxicity against both cancer cell lines with high safety profile to normal fibroblast (HFF-1). In addition, towards SW-620 cell line, both candidates inducted apoptosis and inhibited anti-apoptotic Bcl2 and BclxL proteins in a dose dependent manner. Collectively, the high potency and selective cytotoxicity suggested that conjugates <bold>7c</bold> and <bold>7g</bold> could serve as lead compounds for further optimisation to develop novel antitumor agents and Bcl2/BclxL inhibitors.</p></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Experimental</title><sec id="S0004-S2001" disp-level="2"><label>4.1.</label><title>Chemistry</title><sec id="S0004-S2001-S3001" disp-level="3"><label>4.1.1.</label><title>General</title><p>The NMR spectra have been recorded by Bruker spectrometer at 400&#x02009;MHz. <sup>13&#x02009;</sup>C NMR spectra were run at 100&#x02009;MHz in deuterated dimethylsulphoxide (DMSO-<italic>d6</italic>). Chemical shifts (<italic>&#x003b4;<sub>H</sub></italic>) are reported relative to the solvent (DMSO-<italic>d<sub>6</sub></italic>). Infra-red spectra were recorded on Schimadzu FT-IR 8400S spectrophotometer. Elemental analyses have been performed at the Regional Centre for Microbiology and Biotechnology, Al-Azhar University, Cairo, Egypt.</p></sec><sec id="S0004-S2001-S3002" disp-level="3"><label>4.1.2.</label><title>Synthesis of the target compounds 7a-j and 9a-e</title><p>To hot stirred solution of 1<italic>H</italic>-indole-3-carbohydrazide <bold>5</bold> (0.3&#x02009;g, 1.7&#x02009;mmole) in 15&#x02009;ml of glacial acetic acid, an equivalent amount of appropriate isatin derivatives <bold>6a-j</bold> and <bold>8a-e</bold> was added. The reaction mixture was heated under reflux for (5&#x02013;7) h, and then was cooled to room temperature. The formed precipitate was collected by filtration, washed with cold water, hexane and recrystallized from DMF-MeOH mixture to furnish the targeted novel compounds <bold>7a-j</bold> and <bold>9a-e</bold>, respectively. Representative NMR spectra charts were provided in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1862100">Supplementary data</ext-link>.</p><sec id="S0004-S2001-S3002-S4001" disp-level="4"><label>4.1.2.1.</label><title>N'-(2-Oxoindolin-3-ylidene)-1H-indole-3-carbohydrazide 7a</title><p>Yellow powder; m.p. 259&#x02013;261&#x02009;&#x000b0;C; (yield 81%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 6.93 (d, 0.3H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 6.98 (d, 0.7H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.07&#x02013;7.16 (<italic>m</italic>, 1H, Ar-H), 7.22&#x02013;7.29 (<italic>m</italic>, 2H, Ar-H), 7.37 (<italic>t</italic>, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.52&#x02013;7.58 (<italic>m</italic>, 1H, Ar-H), 7.65 (d, 0.7H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.13 (d, 0.3H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.23&#x02013;8.32 (<italic>m</italic>, 1.7H, Ar-H), 8.67 (<italic>s</italic>, 0.3H, Ar-H), 10.83, 13.45 (<italic>s</italic>, 1H, NH of isatin), 11.18, 11.30 (<italic>s</italic>, 1H, hydrazide NH), 12.01, 12.05 (<italic>s</italic>, 1H, indole NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 107.50, 108.17, 110.96, 111.56, 112.56, 112.99, 116.14, 120.75, 120.96, 120.98, 121.73, 121.79, 121.97, 122.21, 123.03, 123.21, 126.19, 126.54, 127.75, 131.51, 132.48, 133.62, 136.22, 136.65, 136.78, 142.41, 143.91 (Aromatic carbons), 162.16, 163.37 (C=O hydrazide), 165.27, 165.65 (C=O isatin)); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3504, 3280, 3245 (3NH) and 1707, 1654 (2&#x02009;C=O); Calcd. Anal. for C<sub>17</sub>H<sub>12</sub>N<sub>4</sub>O<sub>2</sub>: C, 67.10; H, 3.97; N, 18.41; found C, 66.83; H, 4.57; N, 18.41.</p></sec><sec id="S0004-S2001-S3002-S4002" disp-level="4"><label>4.1.2.2.</label><title>N'-(5-Fluoro-2-oxoindolin-3-ylidene)-1H-indole-3-carbohydrazide 7b</title><p>Red powder; m.p. &#x0003e;300&#x02009;&#x000b0;C; (yield 78%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 6.90&#x02013;9.93 (<italic>m</italic>, 0.7H, Ar-H), 6.96&#x02013;7.00 (<italic>m</italic>, 0.3H, Ar-H), 7.20&#x02013;7.30 (<italic>m</italic>, 3H, Ar-H), 7.49&#x02013;7.58 (<italic>m</italic>, 1.3H, Ar-H), 8.15 (d, 0.7H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.23 (d, 0.3H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.31 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.72 (<italic>s</italic>, 0.7H, Ar-H), 10.84, 13.41 (<italic>s</italic>, 1H, NH of isatin), 11.31, 11.35 (<italic>s</italic>, 1H, hydrazide NH), 12.03 (<italic>s</italic>, 1H, indole NH); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3659, 3460, 3285 (3NH) and 1712, 1669 (2C=O); Calcd. Anal. for C<sub>17</sub>H<sub>11</sub>FN<sub>4</sub>O<sub>2</sub>: C, 63.35; H, 3.44; N, 17.38; found C, 63.14; H, 4.01; N, 17.37.</p></sec><sec id="S0004-S2001-S3002-S4003" disp-level="4"><label>4.1.2.3.</label><title>N'-(5-Chloro-2-oxoindolin-3-ylidene)-1H-indole-3-carbohydrazide 7c</title><p>Yellow powder; m.p. &#x0003e;300&#x02009;&#x000b0;C; (yield 75%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 6.92 (d, 0.7H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz), 6.97 (d, 0.3H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz), 7.20&#x02013;7.29 (<italic>m</italic>, 2H, Ar-H), 7.39&#x02013;7.43 (<italic>m</italic>, 1H, Ar-H), 7.51&#x02013;7.58 (<italic>m</italic>, 1H, Ar-H), 7.64 (<italic>s</italic>, 0.3H, Ar-H), 8.22&#x02013;8.35 (<italic>m</italic>, 2H, Ar-H), 8.71 (<italic>s</italic>, 0.7H, Ar-H), 10.95, 12.03 (<italic>s</italic>, 1H, NH of isatin), 11.43 (<italic>s</italic>, 1H, hydrazide NH), 12.03 (<italic>s</italic>, 1H, Indole NH); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3593, 3429, 3331 (3NH) and 1720, 1643 (2&#x02009;C=O); Calcd. Anal. for C<sub>17</sub>H<sub>11</sub>ClN<sub>4</sub>O<sub>2</sub>: C, 60.28; H, 3.27; N, 16.54; found C, 59.77; H, 3.88; N, 16.37.</p></sec><sec id="S0004-S2001-S3002-S4004" disp-level="4"><label>4.1.2.4.</label><title>N'-(5-Bromo-2-oxoindolin-3-ylidene)-1H-indole-3-carbohydrazide 7d</title><p>Orange powder; m.p. 247&#x02013;249&#x02009;&#x000b0;C; (yield 83%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 6.91 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.20&#x02013;7.29 (<italic>m</italic>, 2H, Ar-H), 7.51 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.55 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.73 (<italic>s</italic>, 1H, Ar-H), 8.23 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.34 (<italic>s</italic>, 1H, Ar-H), 11.34 (<italic>s</italic>, 1H, NH of isatin), 12.04 (<italic>s</italic>, 1H, hydrazide NH), 13.31 (<italic>s</italic>, 1H, Indole NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 107.76, 111.54, 112.97, 113.46, 114.78, 121.03, 122.02, 122.86, 123.24, 126.36, 133.58, 133.92, 136.70, 141.39, 142.39 (Aromatic carbons), 162.99 (C=O hydrazide), 163.35 (C=O isatin)); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3621, 3428, 3184 (3NH) and 1710, 1638 (2&#x02009;C=O); Calcd. Anal. for C<sub>17</sub>H<sub>11</sub>BrN<sub>4</sub>O<sub>2</sub>: C, 53.28; H, 2.89; N, 14.62; found C, 52.79; H, 2.82; N, 14.63.</p></sec><sec id="S0004-S2001-S3002-S4005" disp-level="4"><label>4.1.2.5.</label><title>N'-(5-Methyl-2-oxoindolin-3-ylidene)-1H-indole-3-carbohydrazide 7e</title><p>Red powder; m.p. 201&#x02013;203&#x02009;&#x000b0;C; (yield 74%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 1.93, 2.33 (<italic>s</italic>, 3H, CH<sub>3</sub>), 6.85 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.16 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.22&#x02013;7.29 (<italic>m</italic>, 2H, Ar-H), 7.45 (<italic>s</italic>, 1H, Ar-H), 7.55 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.23&#x02013;8.27 (<italic>m</italic>, 2H, Ar-H), 11.17 (<italic>s</italic>, 1H, NH of isatin), 12.04 (<italic>s</italic>, 1H, hydrazide NH), 13.44 (<italic>s</italic>, 1H, Indole NH)); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3451, 3322, 3252 (3NH) and 1711, 1660 (2&#x02009;C=O); Calcd. Anal. for C<sub>18</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>: C, 67.92; H, 4.43; N, 17.60; found C, 67.25; H, 4.98; N, 17.57.</p></sec><sec id="S0004-S2001-S3002-S4006" disp-level="4"><label>4.1.2.6.</label><title>N'-(5-Methoxy-2-oxoindolin-3-ylidene)-1H-indole-3-carbohydrazide 7f</title><p>Red powder; m.p. 197&#x02013;199&#x02009;&#x000b0;C; (yield 80%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 3.81(<italic>s</italic>, 3H, OCH<sub>3</sub>), 6.89 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 6.95 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.19 (<italic>s</italic>, 1H, Ar-H), 7.22&#x02013;7.29 (<italic>m</italic>, 2H, Ar-H), 7.55 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.22&#x02013;8.26 (<italic>m</italic>, 2H, Ar-H), 11.11 (<italic>s</italic>, 1H, NH of isatin), 12.05 (<italic>s</italic>, 1H, hydrazide NH), 13.52 (<italic>s</italic>, 1H, Indole NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 56.09 (OCH3), 106.08, 108.20, 112.35, 112.99, 117.66, 120.94, 121.51, 121.96, 123.21, 126.12, 131.77, 136.07, 136.79, 155.87 (Aromatic carbons), 162.04 (C=O hydrazide), 163.51 (C=O isatin)); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3569, 3432, 3174 (3NH) and 1686, 1655 (2&#x02009;C=O); Calcd. Anal. for C<sub>18</sub>H<sub>14</sub>N<sub>4</sub>O<sub>3</sub>: C, 64.67; H, 4.22; N, 16.76; found C, 64.09; H, 4.76; N, 16.56.</p></sec><sec id="S0004-S2001-S3002-S4007" disp-level="4"><label>4.1.2.7.</label><title>N'-(2-Oxo-5-(trifluoromethoxy)indolin-3-ylidene)-1H-indole-3-carbohydrazide 7g</title><p>Yellow powder; m.p. 278&#x02013;280&#x02009;&#x000b0;C; (yield 72%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 7.05 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.23&#x02013;7.29 (<italic>m</italic>, 2H, Ar-H), 7.36 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.55&#x02013;7.60 (<italic>m</italic>, 2H, Ar-H), 8.22 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.31 (<italic>s</italic>, 1H, Ar-H), 11.46 (<italic>s</italic>, 1H, NH of isatin), 12.06 (<italic>s</italic>, 1H, hydrazide NH), 13.39 (<italic>s</italic>, 1H, Indole NH)); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3647, 3445, 3187 (3NH) and 1710, 1641 (2&#x02009;C=O); Calcd. Anal. for C<sub>18</sub>H<sub>11</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>: C, 55.68; H, 2.86; N, 14.43; found C, 55.53; H, 2.91; N, 14.39.</p></sec><sec id="S0004-S2001-S3002-S4008" disp-level="4"><label>4.1.2.8.</label><title>N'-(5-Nitro-2-oxoindolin-3-ylidene)-1H-indole-3-carbohydrazide 7h</title><p>Yellow powder; m.p. &#x0003e;300&#x02009;&#x000b0;C; (yield 86%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 7.12 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.22&#x02013;7.29 (<italic>m</italic>, 2H, Ar-H), 7.54 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.20 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.24 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.30&#x02013;8.34 (<italic>m</italic>, 2H, Ar-H), 11.89 (<italic>s</italic>, 1H, NH of isatin), 12.11 (<italic>s</italic>, 1H, hydrazide NH), 13.19 (<italic>s</italic>, 1H, Indole NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 107.64, 111.74, 113.00, 115.84, 120.96, 121.46, 121.92, 122.10, 123.31, 127.21, 132.40, 133.29, 136.71, 143.24, 147.41 (Aromatic carbons), 163.65 (C=O hydrazide), 166.06 (C=O isatin)); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3594, 3426, 3111 (3NH) and 1704, 1671 (2&#x02009;C=O); Calcd. Anal. for C<sub>17</sub>H<sub>11</sub>N<sub>5</sub>O<sub>4</sub>: C, 58.46; H, 3.17; N, 20.05; found C, 57.91; H, 3.71; N, 20.08.</p></sec><sec id="S0004-S2001-S3002-S4009" disp-level="4"><label>4.1.2.9.</label><title>N'-(7-Fluoro-2-oxoindolin-3-ylidene)-1H-indole-3-carbohydrazide 7i</title><p>Yellow powder; m.p. &#x0003e;300&#x02009;&#x000b0;C; (yield 79%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 7.08&#x02013;7.17 (m, 1H, Ar-H), 7.21&#x02013;7.29 (<italic>m</italic>, 2H, Ar-H), 7.31 (<italic>t</italic>, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.50&#x02013;7.58 (<italic>m</italic>, 1H, Ar-H), 8.03 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.31 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.68 (<italic>s</italic>, 1H, Ar-H), 11.29 (<italic>s</italic>, 1H, NH of isatin), 12.05 (<italic>s</italic>, 1H, hydrazide NH), 13.43 (<italic>s</italic>, 1H, Indole NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 107.34, 108.02, 112.57, 113.01, 117.04, 118.17, 118.68, 119.11, 119.28,120.96, 121.72, 122.03, 122.56, 122.97, 123.27, 123.70, 123.92, 126.20, 127.76, 129.12, 129.25, 130.80, 131.97, 133.86, 136.21, 136.78, 145.81, 146.21, 148.22, 148.63 (Aromatic carbons), 162.09, 163.17 (C=O hydrazide), 165.30, 165.44 (C=O isatin)); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3527, 3450, 3286 (3NH) and 1716, 1638 (2&#x02009;C=O); Calcd. Anal. for C<sub>17</sub>H<sub>11</sub>FN<sub>4</sub>O<sub>2</sub>: C, 63.35; H, 3.44; N, 17.38; found C, 63.11; H, 4.08; N, 17.33.</p></sec><sec id="S0004-S2001-S3002-S4010" disp-level="4"><label>4.1.2.10.</label><title>N'-(5,7-Dimethyl-2-oxoindolin-3-ylidene)-1H-indole-3-carbohydrazide 7j</title><p>Red powder; m.p. &#x0003e;300&#x02009;&#x000b0;C; (yield 74%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 2.22 (<italic>s</italic>, 3H, CH<sub>3</sub> of position 7 for isatin), 2.30 (<italic>s</italic>, 3H, CH<sub>3</sub> of position 5 for isatin), 7.00 (<italic>s</italic>, 1H, Ar-H), 7.15&#x02013;7.28 (<italic>m</italic>, 3H, Ar-H), 7.54 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.23&#x02013;8.34 (<italic>m</italic>, 2H, Ar-H), 11.20 (<italic>s</italic>, 1H, NH of isatin), 12.03 (<italic>s</italic>, 1H, hydrazide NH), 13.45 (<italic>s</italic>, 1H, Indole NH); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3528, 3448, 3176 (3NH) and 1711, 1687 (2&#x02009;C=O); Calcd. Anal. for C<sub>19</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>: C, 68.66; H, 4.85; N, 16.86; found C, 68.14; H, 5.37; N, 16.68.</p></sec><sec id="S0004-S2001-S3002-S4011" disp-level="4"><label>4.1.2.11.</label><title>N'-(1-Methyl-2-oxoindolin-3-ylidene)-1H-indole-3-carbohydrazide 9a</title><p>Yellow powder; m.p. 273&#x02013;275&#x02009;&#x000b0;C; (yield 66%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 3.22, 3.26 (<italic>s</italic>, 3H, <italic>N</italic>-CH<sub>3</sub>), 7.10&#x02013;7.18 (<italic>m</italic>, 2H, Ar-H), 7.22&#x02013;7.30 (<italic>m</italic>, 2H, Ar-H), 7.43&#x02013;7.49 (<italic>m</italic>, 1H, Ar-H), 7.53&#x02013;7.58 (<italic>m</italic>, 1H, Ar-H), 7.66 (d, 0.3H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.17 (d, 0.7H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.24&#x02013;8.33 (<italic>m</italic>, 1.3H, Ar-H), 8.67 (<italic>s</italic>, 0.7H, Ar-H), 11.24, 13.38 (<italic>s</italic>, 1H, hydrazide NH), 12.04, 12.07 (<italic>s</italic>, 1H, Indole NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 26.65 (<italic>N</italic>-CH<sub>3</sub>), 108.60, 110.78, 113.46, 120.48, 121.10, 121.34, 122.45, 123.69, 124.03, 126.55, 131.90, 132.33, 137.24, 144.14 (Aromatic carbons), 161.95 (C=O hydrazide), 162.55 (C=O isatin)); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3436, 3117 (2NH) and 1774, 1725 (2&#x02009;C=O); Calcd. Anal. for C<sub>18</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>: C, 67.92; H, 4.43; N, 17.60; found C, 67.65; H, 4.97; N, 17.54.</p></sec><sec id="S0004-S2001-S3002-S4012" disp-level="4"><label>4.1.2.12.</label><title>N'-(2-Oxo-1-propylindolin-3-ylidene)-1H-indole-3-carbohydrazide 9b</title><p>Yellow powder; m.p. 248&#x02013;250&#x02009;&#x000b0;C; (yield 69%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 0.92 (<italic>t</italic>, 3H, &#x02013;CH<sub>2</sub>C<underline>H<sub>3</sub></underline>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 1.65&#x02013;1.74 (<italic>m</italic>, 2H, &#x02013;C<underline>H<sub>2</sub></underline>CH<sub>3</sub>), 3.76 (<italic>t</italic>, 2H, <italic>N</italic>-CH<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.17 (<italic>t</italic>, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.23&#x02013;7.30 (<italic>m</italic>, 3H, Ar-H), 7.44 (<italic>t</italic>, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.55&#x02013;7.58 (<italic>m</italic>, 1H, Ar-H), 7.68 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.23&#x02013;8.25 (<italic>m</italic>, 1H, Ar-H), 8.29 (<italic>s</italic>, 1H, Ar-H), 12.06 (<italic>s</italic>, 1H, hydrazide NH), 13.40 (<italic>s</italic>, 1H, Indole NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 11.67 (&#x02013;CH<sub>2</sub><underline>C</underline>H<sub>3</sub>), 20.95 (&#x02013;<underline>C</underline>H<sub>2</sub>CH<sub>3</sub>), 41.24 (<italic>N</italic>-CH<sub>2</sub>), 108.10, 110.53, 113.00, 120.08, 120.78, 120.94, 122.01, 123.23, 123.45, 126.19, 131.42, 131.84, 134.42, 136.80, 143.00 (Aromatic carbons), 161.51 (C=O hydrazide), 162.10 (C=O isatin)); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3310, 3151 (2NH) and 1727, 1663 (2&#x02009;C=O); Calcd. Anal. for C<sub>20</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>: C, 69.35; H, 5.24; N, 16.17; found C, 69.20; H, 5.73; N, 16.19.</p></sec><sec id="S0004-S2001-S3002-S4013" disp-level="4"><label>4.1.2.13.</label><title>N'-(1-Benzyl-2-oxoindolin-3-ylidene)-1H-indole-3-carbohydrazide 9c</title><p>Yellow powder; m.p. 274&#x02013;276&#x02009;&#x000b0;C; (yield 72%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 5.00 (<italic>s</italic>, 2H, CH<sub>2</sub>), 7.06 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.16 (<italic>t</italic>, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.24&#x02013;7.31 (<italic>m</italic>, 3H, Ar-H), 7.34&#x02013;7.43 (<italic>m</italic>, 5H, Ar-H), 7.57 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.70 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.25 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.32 (<italic>s</italic>, 1H, Ar-H), 12.09 (<italic>s</italic>, 1H, hydrazide NH), 13.35 (<italic>s</italic>, 1H, Indole NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 43.03 (CH<sub>2</sub>), 108.09, 110.81, 113.03, 120.21, 120.86, 120.95, 122.06, 123.28, 123.70, 126.18, 127.83, 128.10, 129.22, 131.33, 131.89, 134.29, 136.20, 136.80, 142.62 (Aromatic carbons), 161.52 (C=O hydrazide), 162.13 (C=O isatin); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3450, 3210 (2NH) and 1748, 1688 (2&#x02009;C=O); Calcd. Anal. for C<sub>24</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>: C, 73.08; H, 4.60; N, 14.20; found C, 72.58; H, 5.14; N, 14.06.</p></sec><sec id="S0004-S2001-S3002-S4014" disp-level="4"><label>4.1.2.14.</label><title>N'-(5-Chloro-2-oxo-1-propylindolin-3-ylidene)-1H-indole-3-carbohydrazide 9d</title><p>Yellow powder; m.p. 262&#x02013;263&#x02009;&#x000b0;C; (yield 70%); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3450, 3221 (2NH) and 1730, 1660 (2&#x02009;C=O); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 0.90 (<italic>t</italic>, 3H, &#x02013;CH<sub>2</sub>C<underline>H<sub>3</sub></underline>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 1.62&#x02013;1.71 (<italic>m</italic>, 2H, &#x02013;C<underline>H<sub>2</sub></underline>CH<sub>3</sub>), 3.72 (<italic>t</italic>, 2H, <italic>N</italic>-CH<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.22&#x02013;7.28 (<italic>m</italic>, 3H, Ar-H), 7.45 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.55 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.65 (<italic>s</italic>, 1H, Ar-H), 8.22 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.34 (<italic>s</italic>, 1H, Ar-H), 12.06 (<italic>s</italic>, 1H, hydrazide NH), 13.26 (<italic>s</italic>, 1H, Indole NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 11.61 (&#x02013;CH<sub>2</sub><underline>C</underline>H<sub>3</sub>), 20.89 (&#x02013;<underline>C</underline>H<sub>2</sub>CH<sub>3</sub>), 41.37 (<italic>N</italic>-CH<sub>2</sub>), 107.71, 112.06, 112.55, 112.99, 120.35, 120.99, 121.81, 122.06, 123.26, 126.35, 127.70, 130.66, 133.15, 136.73, 141.63 (Aromatic carbons), 161.28 (C=O hydrazide), 162.20 (C=O isatin); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3450, 3210 (2NH) and 1748, 1688 (2&#x02009;C=O); Calcd. Anal. for C<sub>20</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>2</sub>: C, 63.08; H, 4.50; N, 14.71; found C, 62.89; H, 4.94; N, 14.71.</p></sec><sec id="S0004-S2001-S3002-S4015" disp-level="4"><label>4.1.2.15.</label><title>N'-(5-Bromo-2-oxo-1-propylindolin-3-ylidene)-1H-indole-3-carbohydrazide 9e</title><p>Orange powder; m.p. 255&#x02013;256&#x02009;&#x000b0;C; (yield 75%); <sup>1</sup>H NMR <italic>&#x003b4; ppm</italic>: 0.95 (<italic>t</italic>, 3H, &#x02013;CH<sub>2</sub>C<underline>H<sub>3</sub></underline>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 1.70&#x02013;1.79 (<italic>m</italic>, 2H, &#x02013;C<underline>H<sub>2</sub></underline>CH<sub>3</sub>), 3.78 (<italic>t</italic>, 2H, <italic>N</italic>-CH<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 6.94 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.21&#x02013;7.30 (<italic>m</italic>, 2H, Ar-H), 7.51 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.55 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.75 (<italic>s</italic>, 1H, Ar-H), 8.24 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.35 (<italic>s</italic>, 1H, Ar-H), 12.10 (<italic>s</italic>, 1H, hydrazide NH), 13.29 (<italic>s</italic>, 1H, Indole NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 11.62 (&#x02013;CH<sub>2</sub><underline>C</underline>H<sub>3</sub>), 20.89 (&#x02013;<underline>C</underline>H<sub>2</sub>CH<sub>3</sub>), 41.35 (<italic>N</italic>-CH<sub>2</sub>), 107.68, 112.51, 112.99, 115.33, 121.00, 122.05, 122.17, 123.04, 123.25, 126.36, 132.37, 132.98, 133.45, 136.72, 142.00 (Aromatic carbons), 161.13 (C=O hydrazide), 162.22 (C=O isatin); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3450, 3179 (2NH) and 1745, 1688 (2&#x02009;C=O); Calcd. Anal. for C<sub>20</sub>H<sub>17</sub>BrN<sub>4</sub>O<sub>2</sub>: C, 56.48; H, 4.03; N, 13.17; found C, 56.06; H, 4.43; N, 13.16.</p></sec></sec></sec><sec id="S0004-S2002" disp-level="2"><label>4.2.</label><title>Biological evaluation</title><sec id="S0004-S2002-S3001" disp-level="3"><label>4.2.1.</label><title>Cell culture</title><p>HT29 and SW620 colorectal cancer cell lines and HFF-1 fibroblast (ATCC, Rockville, USA) were used. HT29 cells were cultured and maintained in Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM) (GIBCO, by Thermo Fischer Scientific, NY, USA) supplemented with 10% foetal bovine serum (FBS), 100 units/mL penicillin, and 100&#x02009;&#x000b5;g streptomycin. SW620 and HFF-1 cells were cultured in Roswell Park Memorial Institute medium (RPMI-1640) (GIBCO, by Thermo scientific, NY, USA) supplemented with 10% FBS and 1% penicillin and streptomycin (Napolitano et&#x000a0;al., 2015). All cultures were incubated at 37&#x02009;&#x000b0;C and humidified atmosphere of 5% CO<sub>2</sub>.</p></sec><sec id="S0004-S2002-S3002" disp-level="3"><label>4.2.2.</label><title>Cell viability assay</title><p>The cytotoxicity effect of compounds on the colorectal cancer cell lines, HT29 and SW620 in addition to the normal human fibroblasts was measured by MTT (3&#x02013;(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma-Aldrich, St. Louis, MO, USA) as previously described<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref>. Briefly, cells were seeded in 96 well culture plates at 5000/well for HT29 and 10,000/well for SW620 for 24&#x02009;h. Cells were then incubated with different compounds from WAG1 series (1&#x02013;15) 24&#x02009;h at 37&#x02009;&#x000b0;C and humidified 5% CO<sub>2</sub> incubator. Freshly prepared 10&#x02009;&#x000b5;l of 3&#x02013;(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT 5&#x02009;mM) solution were added to the cells and further incubated for 2&#x02009;h. Thereafter, 100&#x02009;&#x000b5;l of dimethyl sulphoxide (DMSO) were added in each well and the crystals were dissolved through careful pipetting. In certain experiment, cells were treated different concentration of 5FU for 72&#x02009;h. The absorbance of the product was measured at 540&#x02009;nm using a Synergy&#x02122; 2 multi-mode microplate reader (Biotech, VA, USA). The experiments were performed in triplicate for each condition.</p></sec><sec id="S0004-S2002-S3003" disp-level="3"><label>4.2.3.</label><title>Measurement of apoptosis by annexin V-FITC/PI assay:</title><p>Induction of apoptosis was measured by Dead Cell Apoptosis Kit with Annexin V FITC and PI, for flow cytometry (Thermofischer scientific, OR, USA) according to the manufacturer&#x02019;s instruction. As described previously (39), cells were seeded in a 6-well plate (3&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells per well) and treated with the various compound for 24&#x02009;h. Both floating and adherent cells were harvested, pooled together, and incubated with Annexin V-FITC and PI for 15&#x02009;min on ice in dark. The cells were analysed by BD FACSCalibur&#x02122; cell analyser (BD Biosciences, CA, USA) at an emission of 530&#x02009;nm (FL1 channel) and &#x0003e;575&#x02009;nm (FL3).</p></sec><sec id="S0004-S2002-S3004" disp-level="3"><label>4.2.4.</label><title>Western blot analysis:</title><p>All cells were seeded in a 100&#x02009;mm dish (1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells per dish) in 5% CO<sub>2</sub> at 37&#x02009;&#x000b0;C in the appropriate culture medium. The cells with around 50% confluency were treated with compounds for 24&#x02009;h. At the experiment day, cells were washed with 1x PBS, harvested and lysed in RIPA lysis buffer, combined with protease inhibitors, (Sigma-Aldrich, St. Louis, MO, USA) as described previously<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref>). The total protein concentration was evaluated by the colorimetric Bradford protein assay (BIO-RAD inc, CA, USA) at 595&#x02009;nm absorbance. Lysates were loaded in equal concentration and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to a nitrocellulose membrane by semi-dry. Blocking of the membrane was done by 5% non-fat dried milk for one hour, incubated with the primary antibodies. The primary antibodies used were Bcl2 (cat. no. sc-7382), BclxL (cat. no. sc-8392) and &#x003b2; Actin (cat. no. sc-69879) from (Santa Cruz Biotechnology, Inc., Dallas, TX, USA). The secondary antibodies used were goat anti-mouse IgG-HRP (cat. no. sc-2005) and mouse anti-rabbit IgG-HRP (cat. no. sc-2357) from (Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Detection was done with Luminol HRP chemiluminescence substrate (cat. no. sc-2048) from (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and then visualised by c-digit blot-scanner (LI-COR, Nebraska, USA).</p></sec><sec id="S0004-S2002-S3005" disp-level="3"><label>4.2.5.</label><title>Statistical analysis</title><p>The statistical analysis by the one-way ANOVA test was performed by GraphPad prism. Results were considered significant if the <italic>p-Values</italic> were &#x0003c;0.05.</p></sec></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM0360"><caption><title>Supplemental Material</title></caption><media xlink:href="IENZ_A_1862100_SM0360.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group>
<article-title>Cancer statistics 2016. CA</article-title>. <source>Cancer J Clin</source>
<year>2016</year>;<volume>66</volume>:<fpage>7</fpage>&#x02013;<lpage>30</lpage>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farber</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Diamond</surname><given-names>LK.</given-names></name></person-group>
<article-title>Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid</article-title>. <source>N Engl J Med</source>
<year>1948</year>;<volume>238</volume>:<fpage>787</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">18860765</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadler</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fuks</surname><given-names>JZ</given-names></name>, <name name-style="western"><surname>Wiernik</surname><given-names>PH.</given-names></name></person-group>
<article-title>Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds</article-title>. <source>J Clin Pharmacol</source>
<year>1986</year>;<volume>26</volume>:<fpage>491</fpage>&#x02013;<lpage>509</lpage>.<pub-id pub-id-type="pmid">2944917</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nitiss</surname><given-names>JL.</given-names></name></person-group>
<article-title>DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage</article-title>. <source>Curr Opin Investig Drugs</source>
<year>2002</year>;<volume>3</volume>:<fpage>1512</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nitiss</surname><given-names>JL.</given-names></name></person-group>
<article-title>Targeting DNA topoisomerase II in cancer chemotherapy</article-title>. <source>Nat Rev Cancer</source>
<year>2009</year>;<volume>9</volume>:<fpage>338</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">19377506</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung-Ong</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Giaever</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nislow</surname><given-names>C.</given-names></name></person-group>
<article-title>DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology</article-title>. <source>Chem Biol</source>
<year>2013</year>;<volume>20</volume>:<fpage>648</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">23706631</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodman</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Wintrobe</surname><given-names>MM.</given-names></name></person-group>
<article-title>Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders</article-title>. <source>J Am Med Assoc</source>
<year>1946</year>;<volume>132</volume>:<fpage>126</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">20997191</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischhaber</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Gall</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Duncan</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Hopkins</surname><given-names>PB.</given-names></name></person-group>
<article-title>Direct demonstration in synthetic oligonucleotides that N,N'-bis(2-chloroethyl)-nitrosourea cross links N1 of deoxyguanosine to N3 of deoxycytidine on opposite strands of duplex DNA</article-title>. <source>Cancer Res</source>
<year>1999</year>;<volume>59</volume>:<fpage>4363</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">10485484</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeVita</surname><given-names>VT</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>E.</given-names></name></person-group>
<article-title>A history of cancer chemotherapy</article-title>. <source>Cancer Res</source>
<year>2008</year>; <volume>68</volume>:<fpage>8643</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">18974103</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espinosa</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Zamora</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Feliu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bar&#x000f3;n</surname><given-names>MG.</given-names></name></person-group>
<article-title>Classification of anticancer drugs &#x02013; a new system based on therapeutic</article-title>. <source>Cancer Treat Rev</source>
<year>2003</year>;<volume>29</volume>:<fpage>515</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">14585261</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansoori</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mohammadi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Davudian</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The different mechanisms of cancer drug resistance: a brief review</article-title>. <source>Adv Pharm Bull</source>
<year>2017</year>;<volume>7</volume>:<fpage>339</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">29071215</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baudino</surname><given-names>TA.</given-names></name></person-group>
<article-title>Targeted cancer therapy: the next generation of cancer treatment</article-title>. <source>Curr Drug Discov Technol</source>
<year>2015</year>;<volume>12</volume>:<fpage>3</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">26033233</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topcul</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cetin</surname><given-names>I.</given-names></name></person-group>
<article-title>Endpoint of cancer treatment: targeted therapies. Asian Pac</article-title>
<source>J Cancer Prev</source>
<year>2014</year>; <volume>15</volume>:<fpage>4395</fpage>&#x02013;<lpage>403</lpage>.</mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marone</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ferrandina</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Macchia</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Bcl2, Bax, BclxL and bcl-xs expression in neoplastic and normal endometrium</article-title>. <source>Oncology</source>
<year>2000</year>;<volume>58</volume>:<fpage>161</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">10705244</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hata</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Engelman</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Faber</surname><given-names>AC.</given-names></name></person-group>
<article-title>The Bcl2 family: key mediators of the apoptotic response to targeted anticancer therapeutics</article-title>. <source>Cancer Discov</source>
<year>2015</year>;<volume>5</volume>:<fpage>475</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">25895919</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edlich</surname><given-names>F.</given-names></name></person-group>
<article-title>BCL-2 proteins and apoptosis: recent insights and unknowns</article-title>. <source>Biochem Biophys Res Commun</source>
<year>2018</year>;<volume>500</volume>:<fpage>26</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">28676391</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>D.</given-names></name></person-group>
<source>Means to an End: Apoptosis and other Cell Death Mechanisms</source>. <publisher-loc>Cold Spring Harbor, NY</publisher-loc>: <publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>; <year>2011</year>. ISBN 978-0-87969-888-1.</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spierings</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mcstay</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Saleh</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis</article-title>. <source>Science</source>
<year>2005</year>;<volume>310</volume>:<fpage>66</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">16210526</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>A.</given-names></name></person-group>
<article-title>Aryl hydrocarbon receptor pathway participates in myocardial ischemia reperfusion injury by regulating mitochondrial apoptosis</article-title>. <source>Med Hypotheses</source>
<year>2019</year>;<volume>123</volume>:<fpage>2</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">30696585</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Placzek</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kitada</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A survey of the anti-apoptotic Bcl2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl2 antagonists in cancer therapy</article-title>. <source>Cell Death Dis</source>
<year>2010</year>;<volume>1</volume>:<fpage>e40</fpage>&#x02013;<lpage>e40</lpage>.<pub-id pub-id-type="pmid">21364647</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modugno</surname><given-names>)M</given-names></name>, <name name-style="western"><surname>Banfi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gasparri</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers</article-title>. <source>Exp Cell Res</source>
<year>2015</year>;<volume>332</volume>:<fpage>267</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">25486070</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tarfah Al-Warhi</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Abo-Ashour</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Almahli</surname><given-names>OJ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel [(N-alkyl-3-indolylmethylene)hydrazono]oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl2: synthesis, biological evaluation and in silico studies</article-title>. <source>J Enz Inh Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1300</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>206</volume>:<fpage>112702</fpage>.<pub-id pub-id-type="pmid">32798789</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abo-Ashour</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>George</surname><given-names>RF</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel indole-thiazolidinone conjugates: Design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>160</volume>:<fpage>49</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">30317025</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathur</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nain</surname><given-names>S.</given-names></name></person-group>
<article-title>Recent advancement in synthesis of isatin as anticonvulsant agents: a review</article-title>. <source>Med Chem</source>
<year>2014</year>;<volume>4</volume>:<fpage>417</fpage>&#x02013;<lpage>27</lpage>.</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>C.</given-names></name></person-group>
<article-title>Recent advances in isatin hybrids as potential anticancer agents</article-title>. <source>Arch Pharm (Weinheim)</source>
<year>2020</year>;<volume>353</volume>:<fpage>e1900367</fpage>.<pub-id pub-id-type="pmid">31960987</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Tulsyan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bharadwaj</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mehrotra</surname><given-names>R.</given-names></name></person-group>
<article-title>Systematic review on cytotoxic and anticancer potential of n-substituted isatins as novel class of compounds useful in multidrug-resistant cancer therapy: in silico and in&#x000a0;vitro analysis</article-title>. <source>Top Curr Chem (Cham)</source>
<year>2019</year>;<volume>377</volume>:<fpage>15</fpage>.<pub-id pub-id-type="pmid">31073777</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Aziz</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Ghabbour</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, crystal structure, and biological activity of cis/trans amide rotomers of (Z)-N'-(2-oxoindolin-3-ylidene)formohydrazide</article-title>. <source>J Chem</source>
<year>2014</year>;<volume>2014</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attia</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Afifi</surname><given-names>SA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>New hydrazonoindolin-2-ones: Synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres</article-title>. <source>PLoS One</source>
<year>2017</year>;<volume>12</volume>:<fpage>e0181241</fpage>.<pub-id pub-id-type="pmid">28742842</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Al-Wabli</surname><given-names>RI</given-names></name>, <name name-style="western"><surname>Almutairi</surname><given-names>MS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of certain hydrazonoindolin-2-one derivatives as new potent anti-proliferative agents</article-title>. <source>J Enzym Inhib Med Chem</source>
<year>2018</year>; <volume>33</volume>:<fpage>867</fpage>&#x02013;<lpage>78</lpage>.</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Aziz</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Keeton</surname><given-names>WM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in&#x000a0;vitro pharmacological profiling. Drug Des</article-title>
<source>Dev Ther</source>
<year>2017</year>;<volume>11</volume>:<fpage>2333</fpage>&#x02013;<lpage>46</lpage>.</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abo-Ashour</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: synthesis, in&#x000a0;vitro biological evaluation and in silico insights</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>184</volume>:<fpage>111768</fpage>.<pub-id pub-id-type="pmid">31629164</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Abo-Ashour</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>162</volume>:<fpage>147</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">30445264</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Warhi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>El Kerdawy</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Aljaeed</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, biological evaluation and in silico studies of certain oxindole&#x02013;indole conjugates as anticancer CDK inhibitors</article-title>. <source>Molecules</source>
<year>2020</year>;<volume>25</volume>:<fpage>2031</fpage>.</mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>El Kerdawy</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Al-Ansary</surname><given-names>GH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>163</volume>:<fpage>37</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">30503942</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Almahli</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Al-Ansary</surname><given-names>GH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and in&#x000a0;vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents</article-title>. <source>J Enzym Inhib Med Chem</source>
<year>2017</year>;<volume>32</volume>:<fpage>600</fpage>&#x02013;<lpage>13</lpage>.</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Naggar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Almahli</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel thiazolidinone/thiazolo[3,2-a]benzimidazolone-isatin conjugates as apoptotic anti-proliferative agents towards breast cancer: one-pot synthesis and in&#x000a0;vitro biological evaluation</article-title>. <source>Molecules</source>
<year>2018</year>;<volume>23</volume>:<fpage>1420</fpage>.</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasibhatla</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tseng</surname><given-names>B.</given-names></name></person-group>
<article-title>Why target apoptosis in cancer treatment?</article-title>
<source>Mol Cancer Ther</source>
<year>2003</year>;<volume>2</volume>:<fpage>573</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">12813137</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vaali-Mohammed</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Elwatidy</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Induction of ROS-mediated cell death and activation of the JNK pathway by a sulfonamide derivative</article-title>. <source>Int J Mol Med</source>
<year>2019</year>;<volume>44</volume>:<fpage>1552</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">31364730</pub-id></mixed-citation></ref></ref-list></back></article>